Background:Although immune checkpoint inhibitors (ICIs) have significantly improved cancer treatment, a substantial proportion of patients do not benefit from these therapies, revealing the crucial need to identify reliable biomarkers. Inflammatory markers, such as the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), pan-immune inflammation value (PIV), systemic inflammation response index (SIRI), lactate dehydrogenase (LDH), and C-reactive protein (CRP), may provide insights into treatment outcomes.Objectives: This study aimed to evaluate the prognostic value of multiple inflammatory markers in patients with cancer receiving ICI-based therapies.Methods: A retrospective analysis was performed on 226 patients treated with ICI-based therapies at a single center between 2012 and 2023. The inflammatory markers NLR, PIV, SII, SIRI, LDH, CRP, and albumin were assessed. Cut-off values were determined using maximally selected rank statistics, and overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan–Meier method and Cox regression analysis.Results: High NLR, PIV, SII, SIRI, LDH, and CRP, as well as low albumin levels, were associated with worse OS and PFS (p< 0.001). In the multivariate analysis, high CRP, LDH, NLR, PIV, and SII independently predicted worse OS.Conclusions: Our findings confirm the prognostic utility of several inflammatory biomarkers in patients with cancer receiving ICIs, highlighting their potential for treatment stratification. Further studies are necessary to standardize cut-off values and validate these findings across broader, more diverse populations.
背景：尽管免疫检查点抑制剂（ICIs）已显著改善癌症治疗，但仍有相当比例的患者未能从中获益，这凸显了寻找可靠生物标志物的迫切需求。炎症标志物，如中性粒细胞与淋巴细胞比值（NLR）、全身免疫炎症指数（SII）、泛免疫炎症值（PIV）、全身炎症反应指数（SIRI）、乳酸脱氢酶（LDH）和C反应蛋白（CRP），可能为预测治疗结局提供线索。 目的：本研究旨在评估多种炎症标志物在接受ICI治疗的癌症患者中的预后价值。 方法：对2012年至2023年间单中心接受ICI治疗的226例患者进行回顾性分析。评估了炎症标志物NLR、PIV、SII、SIRI、LDH、CRP和白蛋白水平。采用最大选择秩统计法确定截断值，并使用Kaplan-Meier法和Cox回归分析评估总生存期（OS）和无进展生存期（PFS）。 结果：高NLR、PIV、SII、SIRI、LDH、CRP以及低白蛋白水平均与较差的OS和PFS相关（p<0.001）。多变量分析显示，高CRP、LDH、NLR、PIV和SII是OS较差的独立预测因素。 结论：本研究证实了多种炎症生物标志物在接受ICI治疗的癌症患者中的预后作用，提示其在治疗分层中具有潜在价值。未来需进一步研究以标准化截断值，并在更广泛、更多样化的人群中验证这些发现。
肿瘤(癌症)患者之家